查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016263

產後憂鬱症治療市場：依治療方法、治療環境、病患病情嚴重程度及通路分類－2026-2032年全球市場預測

Postpartum Depression Treatment Market by Treatment Type, Treatment Setting, Patient Severity, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，產後憂鬱症治療市場價值將達到 83.5 億美元，到 2026 年將成長至 86.9 億美元，到 2032 年將達到 122.8 億美元，複合年成長率為 5.66%。

主要市場統計數據
基準年 2025 83.5億美元
預計年份：2026年 86.9億美元
預測年份 2032 122.8億美元
複合年成長率 (%) 5.66%

臨床創新、照護模式和報銷變化正在重塑產後憂鬱症的管理：周產期心理健康環境的演變框架。

產後憂鬱症的治療模式正進入一個臨床關注度提升和護理模式多樣化的新階段，這主要得益於治療方法的進步和患者期望的改變。過去，產後憂鬱症的治療選擇有限，且受制於周產期心理健康方面的社會污名，而如今，其特點是臨床路徑更加完善，行為醫學、基層醫療和數位醫療服務提供者之間的合作也更加廣泛。本文概述了推動變革的關鍵因素——臨床創新、護理服務模式的轉變、監管機構的關注以及保險公司的應對——這些因素正在重新定義產後憂鬱症在不同醫療機構中的識別、管理和支持方式。

臨床突破、數位護理創新和綜合服務模式正在融合，重新定義如何在所有護理環境中識別和有效治療產後憂鬱症。

產後憂鬱症的治療格局正在經歷一場變革性的轉變，這主要得益於臨床創新、數位轉型以及醫療服務模式的改變，這些因素共同拓展了治療選擇，並提高了患者的就醫便利性。臨床上，治療方式正從過度依賴傳統抗憂鬱症轉向多管齊下的綜合療法，將心理治療方法與標靶藥物和神經活性物質結合。這種轉變既反映了人們對周產期神經生物學的更深入理解，也體現了越來越多的證據支持快速起效的治療方法和神經類固醇調變器在緩解急性症狀方面的應用。

與關稅相關的供應鏈和籌資策略重組正在再形成產後憂鬱症藥物的取得途徑、交付成本和生產決策。

關稅和貿易相關政策措施會對產後憂鬱症治療藥物的可及性、成本結構和物流可靠性產生連鎖反應，尤其是在活性成分、專用醫療設備或數位硬體依賴海外採購的情況下。 2025年，美國關稅措施導致供應鏈脆弱性受到更嚴格的審查，推高了用於生產神經活性藥物、特定治療方法輸液裝置以及遠距遠端醫療硬體組件的進口原料成本。為因應這些趨勢，製造商正在重新審視籌資策略，並評估關鍵原料在地化生產的可能性，以減輕關稅波動的影響。

透過對治療方法、交付環境、臨床嚴重程度和分銷管道進行深入細分，揭示了每條路徑對獲取和護理設計的影響。

有效的市場區隔始於治療類型。這可以將治療分為非藥物治療和藥物治療，二者的發展軌跡各不相同。非藥物治療包括成熟的心理療法，例如認知行為療法和人際關係療法，以及快速發展的數位化療法，這些療法提供結構化的認知行為療法模組和臨床醫生支持的行為干預。在藥物治療方面，傳統的藥物類別，例如選擇性血清素再回收抑制劑（SSRIs）和血清素-正腎上腺素再回收抑制劑（SNRIs），仍然是治療的基礎，但非典型抗憂鬱症和新型神經活性類固醇調變器正在影響治療流程，尤其是在症狀較嚴重的患者中。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢正在塑造獨特的實施路徑、監管應對措施和醫療服務優先事項。

區域趨勢正在以不同的方式影響美洲、歐洲、中東和非洲以及亞太地區的醫療服務取得、法規環境和醫療服務模式。在美洲，人們越來越重視將孕產婦心理健康納入產科和基層醫療流程，這主要得益於早期篩檢和支持協作式醫療模式的報銷改革等政策優先事項。儘管北美和南美的醫療體系在資源分配和支付結構方面存在差異，但擴大遠端醫療和數位療法的覆蓋範圍，以彌合地域和社會經濟差距，是通用的優先事項。

為製藥公司、數位療法和服務供應商，重點關注證據生成、綜合護理夥伴關係和可擴展的准入模式。

產後憂鬱症治療領域的企業正在調整其在治療方法研發、數位化產品商業化和通路夥伴關係方面的策略，以抓住新的機會。製藥公司持續投資於針對周產期神經生物學的標靶藥物創新，以及現有抗憂鬱症藥物的生命週期策略。同時，專業生物製藥公司正在開發神經活性類固醇調變器和速效藥物，這些藥物有望改善急性產後症狀的臨床表現。此外，數位醫療公司正從概念驗證（PoC）試點階段走向成熟，開發出能夠與電子健康記錄（EHR）和臨床醫生工作流程整合的臨床檢驗方案，從而實現混合式醫療模式。

領導者可採取切實可行的策略步驟，加快循證醫療服務獲取，增強供應韌性，並使商業模式與支付方和提供方的獎勵保持一致。

產業領導者應優先採取一系列切實可行的步驟，將臨床創新轉化為可近且永續的醫療模式。首先，投資產生高品質的真實世界數據（REW）和部署數據，以展示所有醫療環境和疾病嚴重程度的患者療效，從而加強與支付方和醫療系統合作夥伴的對話。其次，在設計產品和服務時，應充分考慮與現有臨床工作流程和電子健康記錄的互通性，確保數位化療法和遠端監測工具能夠減輕臨床醫生的負擔，而不是增加複雜性。第三，實現生產和供應鏈結構的多元化，最大限度地減少關稅對成本波動的影響，並確保關鍵治療材料的及時交付。

採用嚴謹的混合方法研究途徑，結合臨床醫師的訪談、病患病情進展圖譜繪製、文獻整合和情境分析，以獲得實用見解。

本調查方法結合了定性和定量方法，旨在全面深入了解產後憂鬱症的治療動態。主要調查包括對婦產科、精神科和基層醫療的臨床專業人員進行詳細訪談，以及與支付方、醫院採購經理和數位藥物開發商進行對話，以確定營運限制、報銷考量和推廣應用的促進因素。為了補充這些發現，患者進展圖譜記錄了不同醫療機構中與篩檢、治療啟動和治療依從性相關的真實經驗和障礙。

我們將臨床、營運和政策需求整合起來，引導相關人員朝向公平、實證的產後憂鬱症護理轉型。

總之，憂鬱症治療體係正處於一個轉折點，臨床創新、護理模式的重塑以及外部政策因素的共同作用，既帶來了機遇，也帶來了挑戰。非藥物治療方案的拓展、數位療法的興起以及標靶藥物的出現，豐富了臨床路徑；而遠端醫療和居家照護的普及，則提高了新手父母獲得治療的便利性。然而，面對諸如與關稅相關的供應鏈調整以及不斷變化的報銷環境等外部壓力，製藥公司、醫療服務提供者和保險公司需要採取策略性應對措施，以維持治療的可負擔性和連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：產後憂鬱症治療市場（依治療方法分類）

  • 非藥物療法
    • 認知行為療法
    • 數位療法
    • 人際關係療法
  • 藥物治療
    • 非典型抗憂鬱症
    • SNRI
    • SSRI

第9章：產後憂鬱症治療市場（依治療環境分類）

  • 住院治療
    • 綜合醫院
    • 專業精神科中心
  • 門診
    • 診所
    • 居家照護
    • 遠端醫療

第10章：依患者嚴重程度分類的產後憂鬱症治療市場

  • 溫和的
  • 緩和
  • 嚴重

第11章：產後憂鬱症治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 產後憂鬱症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：產後憂鬱症治療市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 產後憂鬱症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國產後憂鬱症治療市場

第16章：中國產後憂鬱症治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sage Therapeutics, Inc.
  • Sumitomo Pharma Co., Ltd.
  • Sunovion Pharmaceuticals Inc.
Product Code: MRR-0372A4B9143E

The Postpartum Depression Treatment Market was valued at USD 8.35 billion in 2025 and is projected to grow to USD 8.69 billion in 2026, with a CAGR of 5.66%, reaching USD 12.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.35 billion
Estimated Year [2026] USD 8.69 billion
Forecast Year [2032] USD 12.28 billion
CAGR (%) 5.66%

Framing the evolving perinatal mental health environment where clinical innovations, care models, and reimbursement shifts are reshaping postpartum depression management

The landscape of postpartum depression treatment is entering a period of intensified clinical focus and care model diversification, shaped by advances in therapeutic modalities and shifting patient expectations. Historically constrained by limited treatment options and stigma surrounding perinatal mental health, the field is now characterized by richer clinical pathways and expanding interfaces between behavioral health, primary care, and digital health providers. This introduction outlines the major vectors of change-clinical innovation, care delivery transformation, regulatory attention, and payer responsiveness-that are redefining how postpartum depression is identified, managed, and supported across care settings.

Clinicians and health system leaders are increasingly integrating evidence-based psychotherapies alongside newer pharmacologic and neuroactive interventions, while digital therapeutics and telemedicine platforms are improving reach and continuity of care. Concurrently, payers and policymakers are placing greater emphasis on maternal mental health as a key determinant of long-term family well-being, prompting revisions in coverage policies and screening protocols. As a result, stakeholders are faced with practical decisions about care pathway design, workforce training, and technology adoption at the same time that supply chain and reimbursement variables introduce complexity. Therefore, it is essential for providers, payers, medical product developers, and health system executives to understand the interplay between emerging clinical options and the operational and financial implications of bringing them to scale.

This report establishes a foundation for those discussions by synthesizing clinical trends, care-setting dynamics, and stakeholder incentives that will shape near-term strategy. The subsequent sections delve into transformative shifts, external policy impacts, segmentation insights, regional dynamics, and practical recommendations to inform strategic choices and operational planning.

Clinical breakthroughs, digital care innovations, and integrated delivery models converging to redefine how postpartum depression is identified and effectively treated across care settings

The treatment landscape for postpartum depression is undergoing transformative shifts driven by clinical innovation, digital disruption, and changes in care delivery that collectively expand therapeutic options and patient access. On the clinical front, there is a clear movement from a narrow reliance on conventional antidepressants toward multimodal approaches that combine psychotherapeutic techniques with targeted pharmacologic and neuroactive agents. This shift reflects both improved understanding of perinatal neurobiology and growing evidence supporting rapid-acting therapies and neurosteroid modulators for acute symptom relief.

In parallel, care delivery is decentralizing. Telemedicine and remote monitoring have matured beyond emergency stopgaps into sustainable care channels that enable more frequent follow-up, medication management, and therapy delivery in the home environment. Digital therapeutics are emerging as validated adjuncts to traditional psychotherapy, offering structured cognitive and behavioral modules that can complement clinician-led treatment. These technology-enabled models are enhancing continuity of care during the critical postpartum window when mobility and access can be limited.

Workforce innovations are also notable; training programs are equipping obstetric, pediatric, and primary care clinicians with screening and brief intervention skills, while collaborative care models embed behavioral health specialists within maternal care teams. Payers and health systems are responding by experimenting with value-based contracts and bundled approaches that incentivize early screening and integrated care. Collectively, these shifts are not only broadening the clinical toolkit but also creating new commercial and operational imperatives for manufacturers, providers, and technology vendors seeking to support scalable, evidence-based maternal mental health services.

Tariff-driven supply chain recalibration and procurement strategies reshaping access, delivery costs, and manufacturing decisions for postpartum depression therapies

Policy actions affecting tariffs and trade can have cascading effects on the availability, cost structure, and logistical reliability of treatments for postpartum depression, particularly where active pharmaceutical ingredients, specialized devices, or digital hardware are sourced internationally. In 2025, tariff measures in the United States have amplified scrutiny of supply chain vulnerabilities and raised the cost of imported inputs used in the manufacture of neuroactive agents, infusion equipment for certain therapies, and components for telehealth hardware. These dynamics have prompted manufacturers to reassess sourcing strategies and to evaluate the feasibility of regionalizing production for critical inputs to reduce exposure to tariff volatility.

The immediate operational consequences include lengthened procurement timelines for certain imported components and selective repricing pressure that payers and providers must absorb or negotiate. For therapies that depend on intravenous delivery systems or specialized infusion devices, incremental tariff-related costs can translate into higher procedural overhead for providers, affecting setting-level decisions about whether to deliver treatments in inpatient, outpatient, or home-based environments. Meanwhile, digital therapeutics and telemedicine platforms face indirect impacts when hardware costs rise, which can influence patient access in lower-income segments.

Strategic responses have included diversification of supplier networks, nearshoring of manufacturing where feasible, and contract restructurings to shift cost risk. Payers and health systems are also revising procurement and formulary strategies to account for potential supply disruptions and cost variability. Over time, these adjustments may accelerate investment into domestic production capacity for high-priority inputs and strengthen public-private dialogues focused on preserving access to essential maternal mental health therapies amid trade policy shifts.

Insightful segmentation across treatment modalities, delivery environments, clinical severity, and distribution channels revealing pathway-specific implications for access and care design

Meaningful market segmentation begins with treatment type, which divides care into non-pharmacological and pharmacological approaches that are each evolving on distinct trajectories. Non-pharmacological care includes established psychotherapies such as cognitive behavioral therapy and interpersonal therapy, alongside the rapid expansion of digital therapeutics that deliver structured CBT modules and clinician-supported behavioral interventions. On the pharmacologic side, traditional classes such as selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors remain foundational, while atypical antidepressants and novel neuroactive steroid modulators are influencing treatment algorithms, particularly for patients with more acute symptom profiles.

Treatment setting is another critical axis that influences patient pathways and resource allocation. Inpatient care remains relevant for severe presentations requiring intensive monitoring, with care delivered in general hospitals and specialty psychiatric centers depending on acuity and comorbidity. Outpatient treatment captures a broader continuum, including clinic-based visits, homecare services that prioritize convenience and continuity in the postpartum period, and telemedicine platforms that extend reach and allow for more flexible scheduling. The interplay between setting and modality shapes clinical workflows and reimbursement approaches.

Patient severity stratification-ranging from mild through moderate to severe-serves as a practical guide for matching intervention intensity to clinical need. Mild presentations may respond to psychotherapy and digitally delivered interventions, whereas moderate and severe cases often necessitate combined pharmacologic and psychotherapeutic strategies and, in some cases, acute care management. Finally, distribution channels determine how treatments reach patients and include hospital pharmacies that support inpatient and clinic dispensing, retail pharmacies that serve community-based needs, and online pharmacies that facilitate home delivery and telehealth follow-through. Together, these segmentation dimensions inform product development priorities, channel strategies, and care design choices that align clinical efficacy with patient access requirements.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific driving distinct adoption pathways, regulatory responses, and care delivery priorities

Regional dynamics shape access, regulatory environments, and care delivery norms in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, there is concentrated attention on integrating maternal mental health into obstetric and primary care pathways, driven by policy emphasis on early screening and reimbursement reforms that support collaborative care models. Health systems in North and South America vary in resource allocation and payer structure, but shared priorities include expanding telehealth and digital therapeutic access to bridge geographic and socioeconomic gaps.

Within Europe, Middle East & Africa, regulatory heterogeneity and varying health system capacities create a mosaic of adoption patterns. Western European countries often lead in reimbursement support for integrated perinatal mental health programs and have established pathways for psychotherapy access, while parts of the Middle East and Africa are focused on workforce development and stigma reduction. Differences in regulatory frameworks for novel neuroactive agents and digital therapeutics also influence the pace of clinical adoption across this broad region.

The Asia-Pacific region demonstrates a dynamic combination of rapid digital health adoption and emerging policy initiatives to address maternal mental health. Countries with advanced digital infrastructure are leveraging telemedicine and app-based support at scale, while other markets prioritize building primary care capacity and community-based service delivery. Across all regions, cross-border collaborations, regulatory harmonization efforts, and investments in local manufacturing and workforce training will be key determinants of equitable access and the sustainability of new treatment models.

Strategic positioning of pharmaceutical, digital therapeutics, and service providers focused on evidence generation, integrated care partnerships, and scalable access models

Companies operating in the postpartum depression treatment space are aligning strategies across therapeutic development, digital productization, and channel partnerships to capture emerging opportunities. Pharmaceutical firms continue to invest in targeted pharmacologic innovation that addresses perinatal neurobiology and in lifecycle strategies for existing antidepressant classes, while specialty biopharmaceutical developers are pursuing neuroactive steroid modulators and rapid-acting agents that may differentiate clinical profiles for acute postpartum presentations. At the same time, digital health companies are maturing from proof-of-concept pilots to clinically validated solutions that integrate with electronic health records and clinician workflows, enabling blended care models.

Commercial organizations are also exploring partnerships with payers and large provider networks to create bundled care offerings and to support reimbursement pathways for combined therapy protocols. Contract manufacturers and supply chain partners are adapting to procurement shifts by expanding regional capabilities and offering risk-mitigation services. Providers and health systems are selectively piloting integrated care teams that include behavioral health specialists, perinatal care coordinators, and remote monitoring platforms to improve screening rates and treatment continuity.

Strategic differentiation increasingly depends on demonstrated clinical outcomes, real-world evidence generation, and interoperability with care delivery systems. Firms that can provide robust evidence of effectiveness, deliver seamless digital-clinical integration, and align commercial models with payer incentives are better positioned to scale. Moreover, organizations that proactively address affordability and access-through innovative contracting, patient support programs, and channel diversification-are poised to achieve stronger adoption across diverse care settings.

Practical strategic moves for leaders to accelerate evidence-based access, strengthen supply resilience, and align commercial models with payer and provider incentives

Industry leaders should prioritize a set of actionable steps to translate clinical innovations into accessible, sustainable care models. First, invest in generating high-quality real-world evidence and implementation data that demonstrate patient outcomes across care settings and severity levels, enabling stronger dialogues with payers and health system partners. Second, design products and services for interoperability with existing clinical workflows and electronic health records, ensuring that digital therapeutics and remote monitoring tools reduce clinician burden rather than add complexity. Third, diversify manufacturing and supply chain arrangements to minimize exposure to tariff-induced cost volatility and to protect delivery timelines for critical therapeutic inputs.

Fourth, cultivate payer partnerships focused on value-based contracting and bundled care pathways that align incentives around screening, early intervention, and continuity of care. Fifth, expand access through hybrid care models that blend clinic-based psychotherapy, homecare supports, and telemedicine follow-up, tailored to patient severity and social determinants. Sixth, prioritize workforce development and clinician training to improve screening fidelity, reduce stigma, and increase the availability of evidence-based psychotherapies in obstetric and primary care settings. Finally, implement patient-centered affordability measures, such as flexible distribution channels and patient support programs, to reduce out-of-pocket barriers and improve adherence during the critical postpartum period.

Taken together, these recommendations form a pragmatic roadmap for leaders aiming to scale effective postpartum depression treatments while maintaining financial and operational resiliency in the face of regulatory and supply-side headwinds.

A rigorous mixed-methods research approach integrating clinician interviews, patient journey mapping, literature synthesis, and scenario analysis for actionable insights

The research methodology combines qualitative and quantitative techniques to produce a robust, multi-dimensional view of postpartum depression treatment dynamics. Primary research includes in-depth interviews with clinical experts across obstetrics, psychiatry, and primary care, alongside conversations with payers, hospital procurement leaders, and digital therapeutics developers to surface operational constraints, reimbursement considerations, and adoption drivers. Supplementing these insights, patient journey mapping captures real-world experiences and barriers across screening, initiation of therapy, and adherence in diverse care settings.

Secondary research synthesizes peer-reviewed clinical literature, regulatory guidance, and publicly available clinical trial registries to validate therapeutic mechanisms, safety profiles, and standard-of-care practices. Health policy documents and reimbursement frameworks are analyzed to identify evolving coverage pathways and coding implications. A cross-validation process integrates primary findings with secondary sources to ensure consistency and to reconcile divergent perspectives.

Analytical approaches include thematic synthesis for qualitative inputs, scenario analysis to explore the implications of supply chain and policy shifts, and payer impact modeling that evaluates reimbursement levers without producing market sizing. Data quality is maintained through triangulation across multiple sources and transparent documentation of assumptions. Ethical considerations and patient privacy are respected throughout data collection, and expert reviewers validate clinical interpretations and strategic implications.

Synthesis of clinical, operational, and policy imperatives guiding stakeholders toward equitable, evidence-driven postpartum depression care transformation

In conclusion, the postpartum depression treatment ecosystem is at an inflection point where clinical innovation, care model redesign, and external policy drivers collectively create both opportunity and complexity. The expansion of non-pharmacological options, growth in digital therapeutics, and emergence of targeted pharmacologic agents are enriching clinical pathways, while decentralization of care through telemedicine and home-based services is improving accessibility for new parents. However, external pressures such as tariff-related supply chain adjustments and evolving reimbursement landscapes require strategic responses from manufacturers, providers, and payers to preserve affordability and continuity of care.

Moving forward, stakeholders who succeed will be those that integrate clinical evidence with practical deployment strategies-aligning product design, channel selection, and payer engagement to the realities of perinatal care. Investment in workforce training, interoperability, and real-world evidence generation will accelerate adoption and inform sustainable reimbursement models. Ultimately, the goal is to ensure that increased therapeutic options translate into measurable improvements in maternal and infant health outcomes by delivering timely, effective, and equitable care across diverse settings and regions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Postpartum Depression Treatment Market, by Treatment Type

  • 8.1. Non-Pharmacological
    • 8.1.1. Cognitive Behavioral Therapy
    • 8.1.2. Digital Therapeutics
    • 8.1.3. Interpersonal Therapy
  • 8.2. Pharmacological
    • 8.2.1. Atypical Antidepressants
    • 8.2.2. Snris
    • 8.2.3. Ssris

9. Postpartum Depression Treatment Market, by Treatment Setting

  • 9.1. Inpatient
    • 9.1.1. General Hospital
    • 9.1.2. Specialty Psychiatric Center
  • 9.2. Outpatient
    • 9.2.1. Clinic
    • 9.2.2. Homecare
    • 9.2.3. Telemedicine

10. Postpartum Depression Treatment Market, by Patient Severity

  • 10.1. Mild
  • 10.2. Moderate
  • 10.3. Severe

11. Postpartum Depression Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Postpartum Depression Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Postpartum Depression Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Postpartum Depression Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Postpartum Depression Treatment Market

16. China Postpartum Depression Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. AstraZeneca
  • 17.7. Eli Lilly and Company
  • 17.8. GlaxoSmithKline plc
  • 17.9. H. Lundbeck A/S
  • 17.10. Johnson & Johnson
  • 17.11. Otsuka Pharmaceutical Co., Ltd.
  • 17.12. Pfizer Inc.
  • 17.13. Sage Therapeutics, Inc.
  • 17.14. Sumitomo Pharma Co., Ltd.
  • 17.15. Sunovion Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INTERPERSONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INTERPERSONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INTERPERSONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ATYPICAL ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ATYPICAL ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ATYPICAL ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SNRIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SNRIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SSRIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SSRIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SSRIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GENERAL HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GENERAL HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GENERAL HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SPECIALTY PSYCHIATRIC CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SPECIALTY PSYCHIATRIC CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SPECIALTY PSYCHIATRIC CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TELEMEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TELEMEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TELEMEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 159. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 160. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 161. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 162. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 163. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 186. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 187. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 188. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 189. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 190. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 195. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 196. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 197. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 198. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 199. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 200. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY INPATIENT, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY OUTPATIENT, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)